SCHEMBL27415413

SCHEMBL27415413

CC(C)(C)OC(=O)N[C@H]1CCc2sc(NC(=O)C3CC3(F)F)cc2C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.36
DRD2 P14416 3/20 0.33
CTSK P43235 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
BTK Q06187 1/20 0.33
KDM1A O60341 2/20 0.32
MAOB P27338 1/20 0.32
NAMPT P43490 1/20 0.32
KMT2A Q03164 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
NFKB1 P19838 1/20 0.31
NFKB2 Q00653 1/20 0.31
RELA Q04206 1/20 0.31
KCNA3 P22001 1/20 0.31
CDK9 P50750 1/20 0.31
JAK2 O60674 2/20 0.31
JAK1 P23458 2/20 0.31
TYK2 P29597 2/20 0.31
JAK3 P52333 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21603867 0.86 TP53 (0.39) EPHX2DRD2CTSKNPC1RAB9A
SCHEMBL28612475 0.85 EPHX2 (0.36) EPHX2DRD2CTSKNPC1RAB9A
SCHEMBL27415416 0.85 NPC1 (0.32) DRD2NPC1RAB9AJAK2JAK1
SCHEMBL27415414 0.80 ALDH1A1 (0.49) NPC1RAB9AKMT2A
SCHEMBL28617407 0.77 PTPN1 (0.36) RAB9ABTKKMT2A
SCHEMBL31563954 0.77 EPHX2 (0.43) EPHX2DRD2CTSKNPC1RAB9A
SCHEMBL31564173 0.76 EPHX2 (0.43) EPHX2DRD2CTSKNPC1RAB9A
SCHEMBL28920819 0.74 KDM4E (0.47) KMT2A
SCHEMBL21604124 0.73 ALDH1A1 (0.42) NPC1RAB9AKMT2ANFKB1NFKB2
SCHEMBL29371263 0.72 NPC1 (0.47) EPHX2DRD2NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 EPHX2 1603/4885DRD2 2807/4885CTSK 1640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.